Ann Arbor, MINCT07531745Now EnrollingIRB Ready

Dravet Syndrome Clinical Trial in Ann Arbor, MI

Access cutting-edge dravet syndrome treatment through this clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.

Sponsored by Ionis Pharmaceuticals, Inc.

Quick Self-Assessment

See if you qualify for this Ann Arbor location

Preparing your pre-screening questions…

Expert Care in Ann Arbor

Access dravet syndrome specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related dravet syndrome treatment provided free

Apply for This Ann Arbor Location

Check if you qualify for this dravet syndrome clinical trial in Ann Arbor, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Ann Arbor

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Ann Arbor site if eligible
  4. 4Begin participation

About This Dravet Syndrome Study in Ann Arbor

The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).

Sponsor: Ionis Pharmaceuticals, Inc.

Who Can Participate

Inclusion Criteria

Participant is aged ≥ 2 to ≤ 12 years old at the time of informed consent.
Participant has at least 1 parent or caregiver ≥ 18 years old who is willing and able to provide informed consent (signed and dated) and attend all scheduled study visits.
Has a documented diagnosis of DS according to the International League Against Epilepsy (ILAE) criteria and as agreed by the Epilepsy Study Consortium, Inc (ESCI).
Has confirmation of a pathogenic or likely pathogenic SCN1A variant.
Must be currently receiving ≥ 1 concomitant ASM at a stable dose/regimen for ≥ 4 weeks prior to informed consent.
Must have all other interventions for epilepsy (including ketogenic diet or VNS) as well as any other concomitant medications including medications for behavioral management, sleep, and supplements or nutritional support stable for ≥ 4 weeks prior to informed consent. Vagus nerve stimulator implantation must have occurred ≥ 6 months prior to informed consent.
Experiences the required number of major motor seizures during the Screening Period. Key

Exclusion Criteria

Known brain or spinal disease that would interfere with the LP procedure or CSF circulation, or presence of other factors that would affect the safety of the LP procedure.
Pathogenic or likely pathogenic variant in another gene that causes epilepsy.
Has had prior treatment with or is currently enrolled in an interventional clinical trial for a gene therapy or for another antisense oligonucleotide (ASO) for the treatment of DS.
Has had treatment with or is currently enrolled in an interventional clinical trial of any other investigational drug, biological agent, or device within 30 days prior to Screening, or 5 half-lives of investigational agent, whichever is longer.
Current treatment with an anti-seizure medication (ASM) acting primarily as a sodium channel blocker, as maintenance treatment.
Prior brain surgeries including: corpus callosotomy, implantation of device for deep brain stimulation or any other palliative brain surgery intended to reduce seizure burden. Note: Other protocol pre-specified inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Ann Arbor?

Yes, this clinical trial (NCT07531745) has an active research site in Ann Arbor, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Dravet Syndrome Treatment Options in Ann Arbor, MI

If you're searching for dravet syndrome treatment options in Ann Arbor, MI, this clinical trial (NCT07531745) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Ann Arbor research site is actively enrolling participants for this clinical trial. You'll receive care from experienced dravet syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all dravet syndrome clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Ann Arbor, MI

See all essential tremor clinical trials recruiting in Ann Arbor — not just this study.

Browse Essential Tremor Trials in Ann Arbor →

Browse More Trials by Condition

Essential Tremor TrialsRheumatoid Arthritis TrialsDravet Syndrome TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Ann Arbor?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Ann Arbor, MI